Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $23.2K | $1.37M | $1.37M | $274M | $332M | $219M | $248M | $480M | $875M |
| Revenue growth | — | — | 5800.9% | -0.0% | 19954.5% | 21.0% | -33.9% | 12.9% | 93.8% | 82.4% |
| Gross profit | $0.00 | -$7.32K | $859K | $536K | $158M | $179M | $15.4M | $34.8M | $196M | $444M |
| Gross margin | — | -31.6% | 62.9% | 39.2% | 57.5% | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Operating income | -$449K | -$5.69M | -$840K | -$6.90M | $153M | $170M | -$407M | -$31.8M | $131M | $276M |
| Operating margin | — | -24574.5% | -61.5% | -504.8% | 55.9% | 51.4% | -185.4% | -12.8% | 27.2% | 31.5% |
| Net income | -$7.43M | $582K | -$950K | -$7.12M | $106M | $133M | -$425M | -$45.8M | $52.1M | $70.8M |
| Net margin | — | 2512.6% | -69.5% | -520.8% | 38.7% | 40.0% | -193.7% | -18.5% | 10.9% | 8.1% |
| EPS (diluted) | -$0.19 | $0.01 | -$0.56 | -$1.96 | $0.18 | $0.22 | -$100.36 | -$10.39 | $9.69 | $10.48 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$274K | -$715K | -$480K | -$4.04M | $86.7M | $173M | $50.6M | $1.26M | $23.2M | $248M |
| Capital expenditures | — | — | $0.00 | $84.0K | $61.2M | $36.9M | $14.6M | $9.50M | $2.30M | $2.53M |
| Free cash flow | — | — | -$480K | -$4.12M | $25.5M | $137M | $36.0M | -$8.24M | $20.8M | $246M |
| Share buybacks | — | — | — | — | — | — | — | $0.00 | $0.00 | $5.00M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10.5K | $9.45K | $119K | $1.07M | $26.9K | $36.1M | $34.3M | $22.0M | $40.6M | $186M |
| Total assets | $511K | $3.33M | $449K | $6.69M | $170K | $395M | $432M | $398M | $655M | $919M |
| Total liabilities | $6.38M | — | $1.95M | $4.83M | $1.30M | $203M | $311M | $319M | $467M | $495M |
| Long-term debt | — | — | $300K | $0.00 | $0.00 | $78.8M | $23.1M | $26.3M | $22.5M | $29.2M |
| Shareholders' equity | -$5.87M | -$997K | -$1.50M | $1.86M | -$1.13M | $115M | $95.9M | $61.5M | $132M | $329M |
| Retained earnings | -$10.2M | -$9.65M | -$5.45M | -$12.6M | -$18.2M | $102M | -$363M | -$409M | -$357M | -$286M |
| Shares (wtd avg diluted) | 39.7M | 116M | 777K | 4.65M | 593M | 593M | 4.23M | 4.41M | 5.49M | 6.76M |
Every figure is extracted from Nutex Health Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.